Syntex participated in a closed meeting of FDA's Arthritis Drugs Advisory Committee May 24-25 to discuss what the committee and FDA would like to seek from companies planning to seek Rx-to-OTC switches for nonsteroidal anti-inflammatory agents, the company told securities analysts July 19. Syntex said that it has not yet submitted an NDA for OTC naproxen, which is being developed under a joint venture with Procter & Gamble. Syntex characterized the meeting as "favorable" and said that the Syntex/P&G joint venture is "on track" to introduce OTC naproxen in the U.S. before the product's patent expires in December 1993.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.